No black box warning on record for Invokana

As of the latest FDA labeling reviewed, Invokana (CANAGLIFLOZIN) does not carry a black box warning. Standard warnings and precautions still apply — see the full Invokana medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Diabetic Ketoacidosis in Patients with Type 1 Diabetes Mellitus and Other Ketoacidosis : Consider ketone monitoring in patients at risk for ketoacidosis, as indicated. Assess for ketoacidosis regardless of presenting blood glucose levels and discontinue INVOKANA if ketoacidosis is suspected. Monitor patients for resolution of ketoacidosis before restarting ( 5.1 ) Lower

No black box warning on record for Invokana

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Diabetic Ketoacidosis in Patients with Type 1 Diabetes Mellitus and Other Ketoacidosis : Consider ketone monitoring in patients at risk for ketoacidosis, as indicated. Assess for ketoacidosis regardless of presenting blood glucose levels and discontinue INVOKANA if ketoacidosis is suspected. Monitor patients for resolution of ketoacidosis before restarting ( 5.1 ) Lower

Invokana Black Box Warning

No black box warning on record for Invokana

Other warnings & precautions

Invokana Black Box Warning

No black box warning on record for Invokana

Other warnings & precautions